Phase 2 Eczema Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older
• People who have been diagnosed with chronic atopic dermatitis (eczema) for at least 6 months before the start of the trial, with the diagnosis confirmed by a photograph
• People whose eczema has not responded well enough to standard treatments (not including systemic immunosuppressants) used for at least 4 consecutive weeks within the past 6 to 12 months, or where a doctor has documented reasons why topical (skin-applied) treatments are not medically appropriate
• People with moderate to severe eczema, meaning a significant portion of the body's skin is affected, based on specific scoring measurements taken at both the screening and baseline appointments (confirm with trial site)
• People in the "bio-experienced" group — meaning those who have previously used biologic medicines (a type of injectable anti-inflammatory treatment) for at least 12 weeks within the past 5 years, and either had a partial or no response, experienced side effects or intolerances, or lost access to those treatments
• People with a body weight above 45 kg (100 lbs) and a body mass index (a measure of body weight relative to height) between 17.5 and 40
• People who are willing and able to attend all scheduled visits, follow the treatment plan, and complete all required tests and study procedures

Who may not be able to join:

• People with significant allergic or autoimmune conditions other than eczema, such as lupus or other complement disorders, Type 1 diabetes, inflammatory bowel disease, or multiple sclerosis (well-controlled mild to moderate cases may be considered — confirm with trial site)
• People with a history of severe allergic reactions, including anaphylaxis, or reactions to protein-based medicines, or known sensitivity to the specific study drugs being tested (people with allergies to a single identifiable, avoidable substance such as peanuts may still be considered if avoiding that substance during the study is possible — confirm with trial site)
• People with any active infection requiring treatment in the 2 weeks before screening, or who were hospitalised for an infection or received intravenous antibiotic treatment within 60 days before the trial start date
• People with an active skin infection requiring systemic antibiotic, antiviral, antifungal, or antiparasitic treatment within 2 weeks before the trial start date, or a surface-level skin infection requiring topical treatment within 1 week before the start date
• People who have had any infection considered serious or opportunistic within 6 months before the trial start date
• People with other inflammatory skin conditions (such as psoriasis, seborrheic dermatitis, or lupus affecting the skin) that could interfere with assessing eczema or the treatment's effects
• People with a medical or psychiatric condition, including recent or current thoughts of suicide or self-harm (within the past year), or abnormal laboratory results, that in the doctor's judgement could make participation unsafe or inappropriate
• People currently using any medications that are not permitted during the trial (confirm with trial site for the specific list)
• People who have had narrowband UVB phototherapy, broadband phototherapy, or regular use of a tanning bed (more than twice a week) within 4 weeks before the trial start date
• People who have taken part in another clinical trial involving an experimental medicine or vaccine within 30 days (or 5 half-lives of that medicine, whichever is longer) before the start of this trial
• People with HIV, hepatitis B, or hepatitis C infections, as determined by specific testing outlined in the trial protocol
• People with evidence of active or latent (inactive but present) tuberculosis (TB), or TB that has not been adequately treated; people currently being treated for active or latent TB are not eligible

Important: Always verify eligibility with the trial site directly before applying.